[C-11]NPA PET-Amphetamine for Cocaine Use Disorder
Trial Summary
Do I have to stop taking my current medications for the trial?
Yes, you must not be on any prescription medical or psychotropic medications to participate in this trial.
What data supports the idea that [C-11]NPA PET-Amphetamine for Cocaine Use Disorder is an effective treatment?
The available research shows that [C-11]NPA is a promising tool for imaging dopamine receptors in the brain, which are involved in addiction. However, the studies mainly focus on its ability to measure dopamine activity rather than directly treating cocaine use disorder. The research indicates that [C-11]NPA is more sensitive to changes in dopamine levels compared to other tracers, which could help in understanding how treatments affect the brain. But there is no direct evidence from these studies that it is an effective treatment for cocaine use disorder itself.12345
What safety data is available for the [C-11]NPA PET-Amphetamine treatment for cocaine use disorder?
The studies provided focus on the use of [11C]NPA as a radiotracer for imaging dopamine D2/3 receptors in the brain, both in nonhuman primates and humans. They evaluate the binding properties and competition with endogenous dopamine, particularly in response to amphetamine administration. However, these studies do not directly address safety data for the treatment of cocaine use disorder. They primarily assess the effectiveness and binding characteristics of the radiotracer in imaging studies. Therefore, specific safety data for the treatment itself is not detailed in the provided research.12356
Is the drug [C-11]NPA PET Scan a promising treatment for Cocaine Use Disorder?
[C-11]NPA PET Scan is a promising drug because it helps to image dopamine receptors in the brain, which are important for understanding and potentially treating conditions like Cocaine Use Disorder. It shows high sensitivity to changes in dopamine levels, making it a valuable tool for studying brain function and the effects of drugs like amphetamine.12345
What is the purpose of this trial?
This study uses \[11C\]NPA positron emission tomography (PET) and a d-amphetamine challenge to image amphetamine induced dopamine release in the striatum in subjects with cocaine use disorders (CUD). Amphetamine-induced dopamine release data from this study will be correlated with \[11C\]NOP-1A VT measured at baseline in the midbrain. \[11C\]NOP-1A PET data will be used from aim 1 (see, Study Record: Imaging CRF X NOP interactions in Cocaine Use Disorders)
Research Team
Rajesh Narendran
Principal Investigator
University of Pittsburgh
Eligibility Criteria
This trial is for men and women aged 18-55 with a diagnosis of cocaine use disorder. Participants must not be on medications, have high blood pressure or heart rate, or be pregnant/breastfeeding. They should not have major psychiatric disorders, severe medical conditions, or a family history of early heart attacks/strokes/psychosis. No heavy recent use of other drugs/alcohol and must have completed a related PET scan in another study.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline PET Scan
Participants undergo a baseline PET scan to measure initial NOP receptor binding
Amphetamine Challenge and PET Scan
Participants receive d-amphetamine and undergo a PET scan to measure dopamine release
Follow-up
Participants are monitored for relapse and other outcomes over a 12-week period
Treatment Details
Interventions
- Baseline [C-11]NPA PET Scan
- d-amphetamine
- Post-amphetamine [C-11]NPA PET Scan
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rajesh Narendran
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator